8th Nov 2013 15:47
For immediate release 8 November 2013
ABCAM PLC
("Abcam" or "the Company")
Result of AGM
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of innovative protein research tools to help life scientists discover more, announces that all resolutions put to its Annual General Meeting held earlier today were duly passed.
For further information please contact:
Abcam | + 44 (0) 1223 696000 |
Jonathan Milner, Chief Executive Officer Jeff Iliffe, Chief Financial Officer www.abcam.com | |
Numis Securities - Nominated Advisor and Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield - Nominated Advisor James Black - Corporate Broking | |
Peel Hunt LLP - Joint Broker | + 44 (0) 207 418 8900 |
Andy Crossley - Corporate Broking | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Notes for editors:
About Abcam plc
Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level to improve the understanding of health and disease.
Abcam is committed to providing scientists with access to the correct reagents and tools for their research. The Company's catalogue currently comprises more than 126,000 products and is continually evolving to meet customer needs. The range offered includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam products are supported with detailed, up-to-date and unbiased data on our website.
Headquartered in Cambridge, UK, Abcam has eight global subsidiary offices and ships to over 100 countries. The Company was founded in 1998, and now employs over 700 people. Abcam is quoted on the AIM market of the London Stock Exchange (AIM: ABC).
To find out more, please visit www.abcam.com
Related Shares:
ABC.L